Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement

Executive Summary

Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.

You may also be interested in...



FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation

Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.

Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says

But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.

Amgen Resolves Repatha Access Kerfuffle With Express Scripts

On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel